Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.

Saunders KO, Nicely NI, Wiehe K, Bonsignori M, Meyerhoff RR, Parks R, Walkowicz WE, Aussedat B, Wu NR, Cai F, Vohra Y, Park PK, Eaton A, Go EP, Sutherland LL, Scearce RM, Barouch DH, Zhang R, Von Holle T, Overman RG, Anasti K, Sanders RW, Moody MA, Kepler TB, Korber B, Desaire H, Santra S, Letvin NL, Nabel GJ, Montefiori DC, Tomaras GD, Liao HX, Alam SM, Danishefsky SJ, Haynes BF.

Cell Rep. 2017 Feb 28;18(9):2175-2188. doi: 10.1016/j.celrep.2017.02.003.

2.

Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies.

Shivatare SS, Chang SH, Tsai TI, Tseng SY, Shivatare VS, Lin YS, Cheng YY, Ren CT, Lee CC, Pawar S, Tsai CS, Shih HW, Zeng YF, Liang CH, Kwong PD, Burton DR, Wu CY, Wong CH.

Nat Chem. 2016 Apr;8(4):338-46. doi: 10.1038/nchem.2463. Epub 2016 Mar 7.

3.

Brugia malayi Antigen (BmA) Inhibits HIV-1 Trans-Infection but Neither BmA nor ES-62 Alter HIV-1 Infectivity of DC Induced CD4+ Th-Cells.

Mouser EE, Pollakis G, Yazdanbakhsh M, Harnett W, de Jong EC, Paxton WA.

PLoS One. 2016 Jan 25;11(1):e0146527. doi: 10.1371/journal.pone.0146527. eCollection 2016.

4.

Exclusive Decoration of Simian Immunodeficiency Virus Env with High-Mannose Type N-Glycans Is Not Compatible with Mucosal Transmission in Rhesus Macaques.

Karsten CB, Buettner FF, Cajic S, Nehlmeier I, Neumann B, Klippert A, Sauermann U, Reichl U, Gerardy-Schahn R, Rapp E, Stahl-Hennig C, Pöhlmann S.

J Virol. 2015 Nov;89(22):11727-33. doi: 10.1128/JVI.01358-15. Epub 2015 Sep 9.

5.

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP.

Science. 2015 Jul 10;349(6244):aac4223. doi: 10.1126/science.aac4223. Epub 2015 Jun 18.

6.

Colorectal mucus binds DC-SIGN and inhibits HIV-1 trans-infection of CD4+ T-lymphocytes.

Stax MJ, Mouser EE, van Montfort T, Sanders RW, de Vries HJ, Dekker HL, Herrera C, Speijer D, Pollakis G, Paxton WA.

PLoS One. 2015 Mar 20;10(3):e0122020. doi: 10.1371/journal.pone.0122020. eCollection 2015.

7.

Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design.

Crispin M, Doores KJ.

Curr Opin Virol. 2015 Apr;11:63-9. doi: 10.1016/j.coviro.2015.02.002. Epub 2015 Mar 6. Review.

8.

HIV-1 envelope glycan moieties modulate HIV-1 transmission.

Shen R, Raska M, Bimczok D, Novak J, Smith PD.

J Virol. 2014 Dec;88(24):14258-67. doi: 10.1128/JVI.02164-14. Epub 2014 Oct 1.

9.

Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL.

Isik G, Sliepen K, van Montfort T, Sanders RW.

PLoS One. 2014 Sep 23;9(9):e107683. doi: 10.1371/journal.pone.0107683. eCollection 2014.

10.

Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.

Raska M, Czernekova L, Moldoveanu Z, Zachova K, Elliott MC, Novak Z, Hall S, Hoelscher M, Maboko L, Brown R, Smith PD, Mestecky J, Novak J.

AIDS Res Ther. 2014 Aug 1;11:23. doi: 10.1186/1742-6405-11-23. eCollection 2014.

11.

HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.

Morales JF, Morin TJ, Yu B, Tatsuno GP, O'Rourke SM, Theolis R Jr, Mesa KA, Berman PW.

J Biol Chem. 2014 Jul 25;289(30):20526-42.

12.

Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Isik G, van Montfort T, Chung NP, Moore JP, Sanders RW.

J Immunol. 2014 May 15;192(10):4628-35. doi: 10.4049/jimmunol.1303401. Epub 2014 Apr 11.

13.

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP.

PLoS Pathog. 2013 Sep;9(9):e1003618. doi: 10.1371/journal.ppat.1003618. Epub 2013 Sep 19.

14.

HIV-1 autologous antibody neutralization associates with mother to child transmission.

Baan E, de Ronde A, Stax M, Sanders RW, Luchters S, Vyankandondera J, Lange JM, Pollakis G, Paxton WA.

PLoS One. 2013 Jul 17;8(7):e69274. doi: 10.1371/journal.pone.0069274. Print 2013.

15.

Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.

Bontjer I, Melchers M, Tong T, van Montfort T, Eggink D, Montefiori D, Olson WC, Moore JP, Binley JM, Berkhout B, Sanders RW.

PLoS One. 2013 Jun 26;8(6):e67484. doi: 10.1371/journal.pone.0067484. Print 2013.

16.

An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells.

Isik G, Chung NP, van Montfort T, Menis S, Matthews K, Schief WR, Moore JP, Sanders RW.

PLoS One. 2013 Jun 24;8(6):e67309. doi: 10.1371/journal.pone.0067309. Print 2013.

17.

Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang LX, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD.

Nat Struct Mol Biol. 2013 Jul;20(7):804-13. doi: 10.1038/nsmb.2600. Epub 2013 May 26.

18.

Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity.

Isik G, van Montfort T, Boot M, Cobos Jiménez V, Kootstra NA, Sanders RW.

PLoS One. 2013;8(4):e60126. doi: 10.1371/journal.pone.0060126. Epub 2013 Apr 2.

19.

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Julien JP, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, Caulfield MJ, King CR, Marozsan AJ, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4351-6. doi: 10.1073/pnas.1217537110. Epub 2013 Feb 20.

20.

A Blueprint for HIV Vaccine Discovery.

Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R.

Cell Host Microbe. 2012 Oct 18;12(4):396-407. doi: 10.1016/j.chom.2012.09.008. Review.

Supplemental Content

Support Center